EGFR-TKI在局部晚期非小细胞肺癌中的应用

随着肺癌分子生物学研究的不断深入,小分子靶点类抗肿瘤药物取得了突破性的进展,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)是其中最受人关注的.多项研究证实了EGFR-TKI具有放射增敏性.放疗单独联合EGFR-TKI可使身体状况差的患者生存获益,但仍不能忽视肺毒性.然而,EGFR-TKI与放化疗联合能否使局部晚期NSCLC患者获益仍存在较大争议.

Application of EGFR-TKI in locally advanced non-small cell lung cancer

With the deepening of the lung cancer molecular biology research,small molecular targets antitumor drugs make breakthrough progress,the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is one of the most attention drug.A series studies show that EGFR-TKI can enhance the antitumor activity of ionizing radiation.Therefore,EGFR-TKI combined with radiotherapy alone for poor-risk patients appears survival benefit,but can't ignore the lung toxicity.However,there is a big contro-versy that EGFR-TKI combined with chemoradiotherapy for locally advanced NSCLC.